EXOSOMM is the first and only company in the world to produce "active milk exosomes" at an "industrial scale, with a shelf life exceeding one year. Our proprietary, patent-protected process sustainably isolates exosomes from cow milk whey—a dairy side-stream—without the use of chemicals, transforming waste into high-value therapeutic solutions for inflammatory diseases. What Are Milk Exosomes? Exosomes are nano-sized vesicles that carry microRNAs, proteins, and lipids, acting as messengers for cellular communication. In milk, these exosomes are naturally bioavailable, surviving digestion and delivering bioactive signals that support immune regulation, gut health, and systemic anti-inflammatory responses. Why Aren’t Milk Exosomes Commercially Available? Despite their immense therapeutic potential, milk exosomes have remained inaccessible at scale due to the complexity of isolating them without damaging their structure or function. Until now, no company has succeeded in developing a scalable, shelf-stable, and biologically active milk exosome product—making EXOSOMM a global first. Manufacturing & Sustainability Highlights - Industrial production capacity: 200 metric tons annually - Chemical-free isolation from cow milk whey - Upcycling dairy waste aligns with ESG goals and reduces input costs - Circular economy model: converting low-value by-products into high-impact bioactives Traction & Strategic Partnerships - Clalit Health Services: Israel’s largest HMO - Tnuva: Israel’s largest food conglomerate - Baemek: Tnuva’s manufacturing facility - Hadassah Medical Center: Completed first-in-human clinical trial - Backed by leading VCs: SOSV, Siddhi Capital, AgFunder - GRAS -Generally Recognized as Safe, regulatory clearance for supplement and food ingredient use